Image (Be85c73b 4817 4f30 A1fc F3014993d209 153 2)
Pemetrexed Dipotassium Injection, Powder, Lyophilized, For Solution
Product Images NDC 83831-111
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pemetrexed Dipotassium (NDC 83831-111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avyxa Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Be85c73b 4817 4f30 A1fc F3014993d209 175 2)
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 01)
Chemical structure diagram of pemetrexed dipotassium, showing its molecular arrangement including potassium carboxylate groups and pyrimidine and phenyl rings.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 02)
A survival curve graph comparing survival probabilities over time (months) between patients treated with Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart displays survival probability on the vertical axis and survival time in months on the horizontal axis, with numbers of patients at risk listed below the graph at various time points.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 03)
A Kaplan-Meier survival curve comparing survival probability over time in months between two groups of patients treated with Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The graph includes the number of patients at risk at predefined time points up to 30 months.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 04)
A Kaplan-Meier survival curve chart comparing survival probability over time in months for two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes patient counts at risk for each group at various time points up to 30 months.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 05)
A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between patients treated with pemetrexed and a placebo. The y-axis represents survival probability, and the x-axis shows survival time in months up to 42 months. The chart includes a table of the number of patients at risk at various time points for both pemetrexed and placebo groups.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 06)
A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between patients treated with Pemetrexed and those given a placebo. The chart includes survival probabilities on the y-axis and survival time in months on the x-axis, with distinct lines for Pemetrexed and placebo groups. A table below shows the number of patients at risk in each group over time.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 07)
A survival probability Kaplan-Meier curve comparing pemetrexed dipotassium injection versus placebo over survival time in months. The graph shows survival probability on the y-axis and time in months on the x-axis, with a table below indicating the number of patients at risk at several time points for both treatment groups.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 08)
A survival probability Kaplan-Meier curve comparing Pemetrexed versus placebo over a 36-month period. The x-axis represents survival time in months, and the y-axis shows survival probability. Patient count at risk is listed below the time axis for both groups at multiple intervals.*
Image (E6c9e0de 4141 4daf 9bab 31d6c394a168 09)
A survival curve graph comparing survival probability over time (in months) between two treatment groups: Pemetrexed + Cisplatin and Cisplatin alone. The graph includes a table of patient risk numbers at various time points for each group, showing declining patient counts over 30 months.*
Pemetrexed For Injection, 100mg/vial- Container Label (E6c9e0de 4141 4daf 9bab 31d6c394a168 10)
Label for Pemetrexed for Injection 100 mg vial, a lyophilized powder for intravenous injection. The label indicates single-dose vial use, includes a hazardous drug warning, and lists Avyxa Pharma, LLC as the manufacturer. It includes dosage details, barcode, lot and expiration placeholders.*
Pemetrexed For Injection, 100mg/vial- Carton Label (E6c9e0de 4141 4daf 9bab 31d6c394a168 11)
The packaging label for Pemetrexed for Injection 100 mg/vial intravenous lyophilized powder by Avyxa Pharma, LLC is shown. The label includes detailed reconstitution instructions, storage conditions, and warnings. It specifies the manufacturer as Avyxa Pharma, LLC with manufacturing in India. The label displays batch details, usage notes, and a barcode.*
Pemetrexed For Injection, 500mg/vial- Container Label (E6c9e0de 4141 4daf 9bab 31d6c394a168 12)
Label for Pemetrexed for Injection 500 mg/vial, lyophilized powder for intravenous use. The label indicates a sterile single-dose vial, with storage instructions and warnings. Manufactured by Avyxa Pharma, LLC, New Jersey, USA. The label includes barcode and lot/expiration fields.*
Pemetrexed For Injection, 500mg/vial- Carton Label (E6c9e0de 4141 4daf 9bab 31d6c394a168 13)
Packaging label for Pemetrexed for Injection 500 mg/vial by Avyxa Pharma, LLC. The lyophilized powder is for intravenous use, supplied as a sterile single-dose vial. Label includes reconstitution instructions, storage conditions, and warnings. The design features a purple and teal color block with the Avyxa logo and barcode.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
